MedTrace Logo

S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer

NCT00003824 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2012-03-09

No results posted yet for this study

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for bladder cancer.

Conditions

Interventions

DRUG

cephalexin

500 mg oral bid for 3 days starting the night before resection

PROCEDURE

surgical procedure

DRUG

Ciprofloxacin

500 mg oral bid for 3 days starting the night before resection

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • David P. Wood, MD · Barbara Ann Karmanos Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-04-30
Primary Completion
2001-07-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003824 on ClinicalTrials.gov